Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular carcinoma

Documenti analoghi

• Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
  di: Lingfeng Diao, et al.
  Pubblicazione: (2024)
• Efficacy and safety of hepatic arterial infusion chemotherapy combined with donafenib in the treatment of unresectable hepatocellular carcinoma
  di: Tao Wan, et al.
  Pubblicazione: (2024)
• Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma
  di: Teh‐Ia Huo, et al.
  Pubblicazione: (2024)
• Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study
  di: Jun‐Zhe Yi, et al.
  Pubblicazione: (2024)
• Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study
  di: Fabio Piscaglia, et al.
  Pubblicazione: (2024)